Growth hormone axis
Tabimorelin
Also called NN703
per administration
It has been used in people, but no trial has settled how much or how often.
The human evidence for Tabimorelin used the oral route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Tabimorelin at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 25–50 mg per administration
- How often
- Every day
- Where
- Oral
- Time to steady level
- ~20 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Tabimorelin describe 25–50 mg per administration. Descriptive only, not a recommendation.
Poorly characterized; an oral secretagogue with limited published human pharmacokinetics.
An orally active growth-hormone secretagogue taken into human study before development stopped; no public trial fixes an oral schedule and the figures in circulation are community-derived, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Tabimorelin (NN703) oral secretagogue literatureAn orally active secretagogue studied in humans; development did not continue and no public trial fixes an oral amount or schedule.